3331
15 minutes ago
Morningstar, 5/2/24:
Librela for canine osteoarthritis got off to a fast start in the US, racking up $40 million in revenue for the first quarter, despite a Wall Street Journal article last month that raised issues about Librela and potential adverse effects,
ZTS reported yeste